# TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

> **NCT06640582** · PHASE1,PHASE2 · RECRUITING · sponsor: **Essen Biotech** · enrollment: 85 (estimated)

## Conditions studied

- Brain Tumor
- Brain Metastases
- Brain Cancer
- Glioma
- Gliomas, Malignant
- Glioblastoma
- Meningioma

## Interventions

- **BIOLOGICAL:** Tumor Infiltrating Lymphocytes (TIL)
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Interleukin-2
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06640582
- **Lead sponsor:** Essen Biotech
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-20
- **Primary completion:** 2026-09-10
- **Final completion:** 2026-12-28
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06640582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06640582, "TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06640582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*